Cough Hypersensitivity Syndrome Market Segments, Analysis, Overview, Outlook Report 2024-2033

The new report published by The Business Research Company, titled Cough Hypersensitivity Syndrome Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $9.71 billion in 2023 to $10.36 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $13.51 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12989&type=smp

Growing Prevalence Of Chronic Respiratory Diseases Boosts The Cough Hypersensitivity Syndrome Market
The rising prevalence of chronic respiratory diseases is expected to propel the growth of the cough hypersensitivity syndrome market going forward. Chronic respiratory diseases (CRDs) refer to a group of long-term diseases that affect the airways and lungs, leading to persistent breathing difficulties and reduced lung function over time. Cough hypersensitivity syndrome treatment reduces discomfort, enhances respiratory health, thereby improving the quality of life for patients suffering from chronic respiratory diseases such as asthma. For instance, in June 2023, according to the Australian Institute of Health and Welfare, an Australia-based national agency, almost one-third (30%) of the Australian population, that is, 7.5 million people, are suffering from chronic respiratory diseases. Additionally, in June 2023, according to the Centers for Disease Control and Prevention, a US-based public health agency, there were 142,342 deaths from chronic lower respiratory diseases in 2021. Therefore, the rising prevalence of chronic respiratory diseases drives the cough hypersensitivity syndrome market.

Integration Of Ai-Powered Algorithms Drives Advancements In The Cough Hypersensitivity Syndrome Market
Major companies operating in the cough hypersensitivity syndrome market are adopting AI-powered algorithms to sustain their position in the market. AI-powered algorithms refer to computational processes and procedures that utilize artificial intelligence (AI) techniques to perform tasks or solve problems. For instance, in April 2021, NuvoAir, a US-based digital healthcare company, launched NuvoAir Cough, a mobile app for detecting cough hypersensitivity syndrome. This is a smartphone app that tracks coughs in domestic settings and is accessible for the iOS operating system. It detects a single cough or burst of coughs using the smartphone's microphone and an artificial intelligence (AI)-powered algorithm. The AI algorithm separates coughs from other sounds using the recorded sound and provides the results back to the user and their clinical physician.

The cough hypersensitivity syndrome market covered in this report is segmented -

1) By Drug Class: Inhales Corticosteroids; Antitussive Agents; Short-acting Beta-2 Agonists; Anticholinergics; Proton Pump Inhibitors; Antihistamines; Other Drugs
2) By Route of Administration: Oral; Inhalation; Other Route Of Administration
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12989&type=discount

Major players in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Cough Hypersensitivity Syndrome Market Report Structure
3. Cough Hypersensitivity Syndrome Market Trends And Strategies
4. Cough Hypersensitivity Syndrome Market - Macro Economic Scenario
5. Cough Hypersensitivity Syndrome Market Size And Growth
…..
27. Cough Hypersensitivity Syndrome Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/cough-hypersensitivity-syndrome-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.